Longeveron LLC is a biotechnology business based in the US. Longeveron LLC shares (LGVN) are listed on the NASDAQ and all prices are listed in US Dollars. Longeveron LLC employs 18 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $5.94 |
|---|---|
| 52-week range | $2.84 - $45.00 |
| 50-day moving average | $8.00 |
| 200-day moving average | $8.63 |
| Wall St. target price | $18.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.88 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.94 from 2022-07-01
| 1 week (2022-06-23) | N/A |
|---|---|
| 1 month (2022-05-31) | N/A |
| 3 months (2022-04-01) | -61.95% |
| 6 months (2022-01-04) | -48.79% |
| 1 year (2021-07-02) | -28.43% |
|---|---|
| 2 years (2020-06-30) | N/A |
| 3 years (2019-06-30) | N/A |
| 5 years (2017-06-30) | N/A |
| Revenue TTM | $1.3 million |
|---|---|
| Gross profit TTM | $590,000 |
| Return on assets TTM | -30.36% |
| Return on equity TTM | -57.38% |
| Profit margin | 0% |
| Book value | $1.64 |
| Market capitalisation | $124.4 million |
TTM: trailing 12 months
We're not expecting Longeveron LLC to pay a dividend over the next 12 months.
Longeveron LLC's shares were split on a 2:5 basis on 11 March 2008. So if you had owned 5 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Longeveron LLC shares – just the quantity. However, indirectly, the new 150% higher share price could have impacted the market appetite for Longeveron LLC shares which in turn could have impacted Longeveron LLC's share price.
Longeveron Inc. , a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.